





HI Global Registry Video






What is the HI Global Registry?













Why should I join?




HI Global Registry

Patient-powered research for a brighter future

- Generate new insights into HI
- Drive new research for treatments and cures
- Support the success of HI clinical trials
- Study and guide standards of care
- Examine factors that influence quality of life
- Improve the lives of all those affected by HI



How do I join?





Surveys

Submit once

- Pregnancy
- Birth

Longitudinal

- Glucose monitoring 6 months
- Quality of life (Parent/ LAR) Annual
- Quality of life (Participant) Annual

Updatable


- Contact information
- Demographics
- Diagnosis
- Medication management
- Diet & feeding management
 - Surgical management
- Other diagnosis
 - Developmental







2020 Annual Report





2020 Annual Report

Davelyn Eaves Hood¹, Tai Pasquini², Lauren Quinlan³, Abigail Linsmeier³, Sunny Chapel³, Isabel Calderón⁴, Julie Raskin⁵

¹CHI Board President & HIGR Principal Investigator, ²CHI Policy & Research Director, ³A2PG, ⁴CHI Board Emeritus and HIGR Investigator, ⁵CHI Executive Director and HIGR Investigator

Address for correspondence

HI Global Registry Investigators c/o Congenital Hyperinsulinism International PO Box 135 Glen Ridge, NJ 07028, USA info@higlobalregistry.org

This report and all of its contents are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast in any form, electronic or mechanical, without the prior written permission of Congenital Hyperinsulinism International (CHI). All rights reserved © 2020 Congenital Hyperinsulinism International



Registry Participation, by the Numbers

HIGR, as of 2/1/2020


Surveys submitted	Participants
Contact	177
Demographics	160
Pregnancy	164
Birth	144
Diagnosis	152
Diet & Feeding	118
Medication	115
Surgery	116
Other Diagnoses	115
Glucose Monitoring	134
Development	113
QOL Parent	129
QOL Participant	10

303 Participants Added
263 Consented
191 Begun Taking Surveys
85 Completed Full Survey
Set
44 Countries Represented

Age	Participant			
	<u> </u>			
0-2 years	92			
3-5 years	95			
6-9 years	39			
10-12 years	16			
13-17 years	18			
18+ years	43			
Youngest	5 weeks			
Oldest	58 years			



HI Prevalence Data





Medication Management

HIGR, as of 1/20/2020

Medication use	# Currently Taking	# Total		
Diazoxide	62	96		
Octreotide	9	32		
Sandostatin LAR	1	4		
Lanreotide	10	14		
Sirolimus	0	2		
Steroids	1	5		
Glucagon (Routine use)	2	21		

Total = Participants who indicated current and/or past use

Side Effects

<u>Diazoxide</u>: Increased body hair, Loss of appetite, <u>Continued</u> hypoglycemia, Swelling, Facial changes

Octreotide: Continued hypoglycemia, Changes in stool, Hyperglycemia, Stomach pain/upset, Gallstones/gallbladder sludge






Diet & Feeding Management

HIGR, as of 1/20/2020

Has the participant experienced any	All Participants	Diffuse			Focal			Other HI Type
feeding issues on a regular basis (check all	W/WO Surgery	No Surgery	Pancrea- tectomy	Total	No Surgery	Pancrea- tectomy	Total	No Reported Surgery
that apply)?	N (%)	N	N	N (%)	N	N	N	N (%)
No feeding issues	31 (32%)	15	2	17 (29%)	0	2	2	12 (40%)
Feeding Issues(s)	67 (68%)	29	14	43 (72%)	1	5	6	18 (60%)
Poor appetite	41 (42%)	17	9	26 (44%)	1	2	3	12 (40%)
Refusing to eat	41 (42%)	17	6	23 (39%)	1	4	5	13 (43%)
Reflux	33 (34%)	18	7	25 (42%)	0	2	2	6 (20%)
Problems with texture	28 (29%)	12	8	20 (34%)	1	2	3	5 (17%)
Gagging	28 (29%)	15	6	21 (36%)	0	1	1	6 (20%)
Vomiting	27 (28%)	13	5	18 (31%)	1	2	3	6 (20%)
Uncoordinated oral skills	22 (22%)	8	7	15 (25%)	1	1	2	5 (17%)
Slow eating	27 (28%)	14	7	21 (36%)	0	0	0	6 (20%)
Coughing	15 (15%)	7	6	13 (22%)	0	0	0	2 (7%)
Overeating	11 (11%)	7	2	9 (15%)	0	1	1	1 (3%)
Other	3 (3%)	0	0	0	0	0	0	3 (10%)
Total	98	44	16	60	1	7	8	30







Parent Quality of Life (QOL)

HIGR, as of 2/1/2020

Age Group of Participants Represented in Parent QOL Survey (N = 101)







Call to Action

- Register.
- Confirm your contact preferences.
- Consent to participate in the surveys.
- Set aside the time to complete ALL surveys.
- Update survey questions.
- Complete longitudinal surveys.





Patient-Driven Research What's Next for HIGR?

- Beginning to fill the gap in published HI literature
- Informing the work of CZI Rare As One Collaborative Research Network
- Supporting clinical trials for new drug development
- Piloting the Rare Disease Cures Accelerator initiative with C-PATH



Considering patients' perspectives makes it more likely that researchers will ask the right questions, conduct the studies best designed to answer them, and produce results more relevant to everyday care and more likely to be adopted in practice.

-- Health Affairs (10.1377/hblog20160519.054923)

